DL-N-methyl-β-cycloheksylalanin | 56564-53-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-N-methyl-β-cycloheksylalanin
• 英文别名: 3-cyclohexyl-2-(methylazaniumyl)propanoate
• CAS: 56564-53-5
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: GBMDYACPQYNUGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  L-苯丙氨酸甲酯 在 platinum(IV) oxide 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 DL-N-methyl-β-cycloheksylalanin
  参考文献：
  名称：

  Use of proton nuclear magnetic resonance spectroscopy for sequence configuration analysis of cyclic tetrapeptides. Structure of tentoxin

  摘要：

  DOI：

  10.1021/ja00846a041

文献信息

• Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
  申请人：——

  公开号：US20020065415A1

  公开（公告）日：2002-05-30

  Described are neuroprotective agents of Formula I 1 wherein R is an amino acid, a derivative thereof, or nitrogen heterocyclic ring which is saturated or unsaturated of from 5 to 8 members which may have additional oxygen or sulfur atoms therein and which may be substituted by one or more substituents selected from: alkyl of from 1 to 4 carbon atoms, hydroxyl, alkoxy of from 1 to 4 carbon atoms, —CF 3 , —CN, -amino, —C(O)R 11 ,or —(CH 2 ) n -aryl of from 6 to 12 carbon atoms; R must be attached through a carbon to the quinoxalinyl ring; R 1 is H, alkyl of from 1 to 4 carbon atoms, phosphonoalkyl of from 1 to 4 carbon atoms, phosphoroalkyl of from 1 to 4 carbon atoms, carboxyalkyl of from 1 to 4 carbon atoms, —(CH 2 ) m C(O)R 11 , or hydroxy; R 2 is hydrogen, hydroxy, or amine; R 3 and R 4 are each independently H, alkyl of from 1 to 4 carbon atoms, cycloalkyl of from 5 to 7 carbon atoms, alkenyl of from 2 to 6 carbon atoms, halogen, haloalkyl of from 1 to 6 carbon atoms, nitro, cyano, SO 2 CF 3 , CH 2 SO 2 R 7 , (CH 2 ) m CO 2 R 7 , (CH 2 ) m CONR 7 R 8 , (CH 2 ) m SO 2 NR 8 R 9 , or NHCOR 7 ; R 5 is H, alkyl of from 1 to 4 carbon atoms, alkenyl of from 2 to 6 carbon atoms, cycloalkyl of from 5 to 7 carbon atoms, halogen, haloalkyl of from 1 to 4 carbon atoms, —(CH 2 ) m aryl of from 6 to 10 carbon atoms, nitro, cyano, SO 2 CF 3 , (CH 2 ) m CO 2 R 9 , (CH 2 ) m CONR 9 R 10 , SO 2 NR 9 R 10 , SO 2 R 7 , (CH 2 ) m SO 2 R 7 , NHCOR 9 , —(CH 2 ) m heterocyclic of from 6 to 10 atoms which may contain nitrogen, oxygen, sulfur, and/or —(CH 2 ) n R; R 5 may be joined at R 4 to form a cyclic aromatic or a heterocyclic ring of from 5 to 7 members which may contain nitrogen, oxygen, or sulfur; R 7 , R 8 , R 9 , and R 10 are each independently selected from hydrogen, alkyl of from 1 to 4 carbon atoms, cycloalkyl of from 5 to 7 carbon atoms, haloalkyl of from 1 to 4 carbon atoms, or —(CH 2 ) m R 11 ; R 11 is alkyl or alkoxy of from 1 to 4 carbon atoms, hydroxy, or amino; m is an integer of from 0 to 4; n is an integer of from 0 to 4; (m may or may not be equal to n); or a pharmaceutically acceptable salt thereof.

  本文描述了公式I1的神经保护剂，其中R是氨基酸、其衍生物或氮杂环环，其饱和或不饱和，由5到8个成员组成，其中可能有额外的氧或硫原子，并且可能被一个或多个取代基所取代，所选的取代基包括：碳链为1到4个碳原子的烷基，羟基，碳链为1到4个碳原子的烷氧基，-CF3，-CN，-氨基，-C（O）R11或-（CH2）n-芳基，其由6到12个碳原子组成；R必须通过一个碳原子连接到喹啉基环上；R1是氢，碳链为1到4个碳原子的烷基，碳链为1到4个碳原子的膦酸烷基，碳链为1到4个碳原子的膦酰烷基，碳链为1到4个碳原子的羧基烷基，-（CH2）mC（O）R11或羟基；R2是氢，羟基或胺基；R3和R4各自独立地是氢，碳链为1到4个碳原子的烷基，环烷基为5到7个碳原子，碳链为2到6个碳原子的烯基，卤素，碳链为1到6个碳原子的卤代烷基，硝基，氰基，SO2CF3，CH2SO2R7，（CH2）mCO2R7，（CH2）mCONR7R8，（CH2）mSO2NR8R9或NHCOR7；R5是氢，碳链为1到4个碳原子的烷基，碳链为2到6个碳原子的烯基，环烷基为5到7个碳原子，卤素，碳链为1到4个碳原子的卤代烷基，-（CH2）maryl，其由6到10个碳原子组成，硝基，氰基，SO2CF3，（CH2）mCO2R9，（CH2）mCONR9R10，SO2NR9R10，SO2R7，（CH2）mSO2R7，NHCOR9，-（CH2）mheterocyclic，其由6到10个原子组成，其中可能含有氮、氧、硫和/或-（CH2）nR；R5可以在R4处连接，形成由5到7个成员组成的环芳香族或杂环环，其中可能含有氮、氧或硫；R7、R8、R9和R10各自独立地选择自氢，碳链为1到4个碳原子的烷基，环烷基为5到7个碳原子，碳链为1到4个碳原子的卤代烷基或-（CH2）mR11；R11是碳链为1到4个碳原子的烷基或烷氧基，羟基或氨基；m是0到4的整数；n是0到4的整数；（m可能等于或不等于n）；或其药学上可接受的盐。
• Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus
  申请人：Doronina Svetlana O.

  公开号：US20090018086A1

  公开（公告）日：2009-01-15

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其中包括C-末端苯丙氨酸残基侧链替换或修饰，这些类似物可以单独提供或通过各种连接剂连接到配体上。相关的结合物可以针对特定细胞类型，提供治疗效果。
• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。
• APELIN POLYPEPTIDES
  申请人：Amgen, Inc

  公开号：EP3674314A2

  公开（公告）日：2020-07-01

  The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

  本发明提供了相对于原生凋亡素-13 多肽具有更高的稳定性、循环半衰期和/或效力的修饰凋亡素多肽。本发明还公开了包含经修饰的凋亡磷多肽的组合物以及使用该多肽治疗心脏疾病（如心力衰竭）的方法。
• Apelin polypeptides
  申请人：AMGEN INC.

  公开号：US10941182B2

  公开（公告）日：2021-03-09

  The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

  本发明提供了相对于原生凋亡素-13 多肽具有更高的稳定性、循环半衰期和/或效力的修饰凋亡素多肽。本发明还公开了包含经修饰的凋亡磷多肽的组合物以及使用该多肽治疗心脏疾病（如心力衰竭）的方法。